[go: up one dir, main page]

WO2000050628A1 - Enantioselective enzymatic hydrolysis of 3-substituted esters of glutaric acid - Google Patents

Enantioselective enzymatic hydrolysis of 3-substituted esters of glutaric acid Download PDF

Info

Publication number
WO2000050628A1
WO2000050628A1 PCT/US2000/004668 US0004668W WO0050628A1 WO 2000050628 A1 WO2000050628 A1 WO 2000050628A1 US 0004668 W US0004668 W US 0004668W WO 0050628 A1 WO0050628 A1 WO 0050628A1
Authority
WO
WIPO (PCT)
Prior art keywords
enantiomeric excess
enantiomer
hydrolysis
formula
carried out
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/004668
Other languages
French (fr)
Inventor
Michael J. Homann
William B. Morgan
Aleksey Zaks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to AU35005/00A priority Critical patent/AU3500500A/en
Publication of WO2000050628A1 publication Critical patent/WO2000050628A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/005—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of carboxylic acid groups in the enantiomers or the inverse reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters

Definitions

  • Substituted oximes are useful pharmaceutical compounds.
  • International Application No. PCT/US98/23255 filed November 18, 1998, describes certain substituted oximes that are useful as neurokinin antagonists.
  • it is desireable to produce a particular enantiomer of the substituted oxime.
  • any efficient enantioselective process for producing a chiral intermediate for these compounds would be a welcome contribution to the art. This invention provides such a contribution.
  • This invention provides a process for preparing an S-enantiomer compound having the formula
  • alkyl means straight or branched hydrocarbon chains of 1 to 6 carbon atoms, optionally substituted with one or more halo, hydroxy, or alkoxy substituents.
  • Alkoxy refers to a group having the formula R-O-, wherein R is alkyl.
  • Aryl refers to a carbocyclic group having at least one aromatic ring (e.g., phenyl or naphthyl), optionally substituted with one or more substituents selected from halo, alkyl, hydroxy, alkoxy, or -CF3.
  • Alkyl refers to a group having the formula aryl-R-, wherein R is alkyl.
  • Cycloalkyl refers to a non-aromatic carbocyclic ring of from 3 to 6 carbon atoms, optionally substituted with one or more substituents selected from halo, alkyl, hydroxy, alkoxy, or -CF3.
  • Cycloalkylalkyl refers to a group having the formula cycloalkyl-R-, wherein R is alkyl.
  • Halo refers to fluorine, chlorine, bromine or iodine.
  • Et refers to an ethyl group.
  • Enantiomeric excess is calculated according to the following formula:
  • R 1 is preferably alkyl, more preferably methyl or ethyl, most preferably ethyl.
  • Enzymes suitable for use in the present process can be identified by carrying out the screening procedure described in Example 1, below.
  • the enzyme is preferably one that is capable of producing an e.e. of the desired compound of at least 80%, more preferably at least 90%.
  • the enzyme is one that produces the S-enantiomer compound in enantiomeric excess.
  • the enzymes used for preparing the S-enantiomer compound of formula (IA) are produced by Candida rugosa , Candida cylindracea , Candida antarctica , and Rhizopus delemar .
  • Examples of enzymes suitable for use in preparing the S-enantiomer compound of formula (IA) include, but are not limited to, the following commercially available enzyme preparations: Altus ChiroCLEC CRO (Candida rugosa); Altus ChiroCLEC-CR (Candida rugosa); Altus Lipase CR Analytical Grade 001-C (Candida rugosa); Biocatalysts Ltd.
  • Candida cylindracea Meito Sangyo LIPASE-OF (Candida cylindracea); Boehringer Mannheim Cholesterol Esterase (Candida rugosa); Boehringer Mannheim CHIRAZYME L-2 (Candida antarctica, fraction B); Fluka Lipase (Candida antarctica); Genzyme Lipase (Candida cyclindracea); Novo Nordisk Novozym 435 (Candida antarctica, type B); Novo Nordisk SP 525 (Candida antarctica, type B); and Seikagaki Lipase (Rhizopus delemar).
  • Boehringer Mannheim CHIRAZYME L-2 in either the dry or liquid form
  • Novo Nordisk Novozym 435 in either the dry or liquid form
  • the enzymes used for preparing the R-enantiomer compound of formula (IB) are obtained from porcine or bovine pancreas.
  • enzymes suitable for use in preparing the R-enantiomer compound of formula (IB) include, but are not limited to, the following commercially available enzyme preparations: Biocatalysts Ltd. Lipase (porcine pancreas); Boehringer Mannheim Lipase (porcine pancreas); Boehringer Mannheim CHIRAZYME L-7 Lipase (porcine pancreas); Rohm Tech COROLASE PP (porcine pancreas); Scientific Protein Labs.
  • ThermoCat 027 Of these commercially available enzyme preparations, Sigma ⁇ - Chymotrypsin Type II and Boehringer Mannheim CHIRAZYME L-7 are particularly preferred.
  • the hydrolysis of compound (II) is preferably carried out at a pH of 5-9, more preferably 6 - 8.5, most preferably 7-8.
  • the substrate concentration is 5% to 25%, more preferably 8% to 12%.
  • the hydrolysis is carried out at a temperature of 25° to 45° C, more preferably, 30° to 40° C.
  • the hydrolysis is preferably carried out in the presence of a buffer (e.g., sodium phosphate or potassium phosphate buffer), and the reaction may, if desired, be titrated with a caustic titrant (e.g., NaOH solution) to maintain the pH within the preferred range.
  • a buffer e.g., sodium phosphate or potassium phosphate buffer
  • a caustic titrant e.g., NaOH solution
  • the concentration of the caustic titrant is 0.2 to 1 M, preferably about 0.5 M.
  • compound (II) is dispersed in a buffer solution by agitation, and the enzyme is subsequently added to the mixture. Upon adding the enzyme, the reaction mixture is agitated until the desired degree of hydrolysis is reached.
  • an enzyme in solid form e.g., adsorbed on beads
  • the reaction may be terminated by removing the enzyme by filtration, and adding acid (e.g., H 2 SO 4 ) to the filtrate to adjust the pH to about 4.0- 4.5, thereby precipitating the desired product.
  • acid e.g., H 2 SO 4
  • the reaction may be terminated by adding acid (e.g., H 2 SO 4 ) to adjust the pH to about 4.0-4.5, and the precipitated product can be recovered by filtration.
  • Compound (II) may be made by conventional means, e.g., as shown in the scheme below: CH 3 COCH 2 COOEt
  • aldehyde (1) is condensed with ethyl acetoacetate in ethyl alcohol with a piperidine catalyst to form crude reaction product (2), a mixture of 2 isomers.
  • the condensation is preferably carried out over 2-3 days at 20°C ⁇ 5°C.
  • Potassium hydroxide is added to the crude reaction product (2), and heated at about 60°-70°C for about one hour to form dipotassium salt (3), which is filtered and washed with ethyl alcohol.
  • the dipotassium salt is dissolved in water and treated with HC1 to form compound (4).
  • Compound (4) is reacted with an alcohol, R ⁇ H (e.g., ethyl alcohol) in the presence of p-toluenesulfonic acid to form compound (II).
  • R ⁇ H e.g., ethyl alcohol
  • Compound (II) may be isolated and purified by adding a higher boiling solvent, (e.g., heptane), distilling off the alcohol, washing with dilute sodium bicarbonate solution to remove the p-toluenesulfonic acid, and cooling the solution to precipitate compound (II).
  • a higher boiling solvent e.g., heptane
  • Enzyme screening reactions were conducted using 1-30 mg enzyme suspended in 0.9 ml of 50 mM sodium phosphate buffer pH 7. The reaction was initiated upon addition of ethyl 3-[3',4'-dichlorophenyl]glutarate (-25 mg) dissolved in 0J ml acetone (10% v/v). Following 48 hours of incubation in 1 dram vials at 30° C with agitation (225 rpm), the reactions were terminated by acidification to a pH of less than 2 using 6N HC1 and extracted with 2 ml ethyl acetate prior to analysis by reverse-phase and chiral HPLC. Enzymes generating the R -monoester or the S -monoester in > 87% enantiomeric excess are summarized in Tables 1 and 2, respectively.
  • Ethyl 3-(3',4'-dichlorophenyl)glutarate (2.45 g, 7.35 mmol) was added to 50 mM KC1 (400 mL) in a 3-neck round bottom flask equipped with an electrode and pH delivery tube connected to a pH stat. The mixture was stirred and adjusted to pH 7-8. ⁇ -chymotrypsin (Sigma Type II; bovine pancreas) (1.25 g) was added and the pH was maintained at pH 8 by automatic titration of 0.5 M NaOH. The reaction was terminated after 114 hours. The reaction mixture was evaporated to dryness and the resultant solid triturated with methyl ene chloride (200 mL).
  • Ethyl 3-[3',4'-dichlorophenyl]glutarate (135 g) was dispersed in 10 mM sodium phosphate buffer pH 8.0 (1215 ml) using an impeller mixer mounted in a 3-neck round bottom jacketed glass flask (3L) equipped with an electrode and pH delivery tube connected to a pH stat. The mixture was stirred and adjusted to pH 8 at 40° C. The reaction was initiated with the addition of 33.75 g of Chirazyme L-2 (adsorbed on beads) and pH 8.0 was maintained by automatic titration of 0.5 M sodium hydroxide. Following 24 hours of incubation, the reaction was 96%> monoester as measured by HPLC. The reaction was terminated by removing the enzyme by filtration.
  • the pH of the filtrate was adjusted to 4.0-4.5 using 20% H 2 SO 4 followed by isolation of the precipitated product by filtration.
  • the acid precipitant was dried (vacuum dryer), and then dissolved in 300 ml of tert -butyl methyl ether (TBME). Insoluble material was removed by filtration through celite.
  • the TBME filtrate was mixed with 400-600 ml of n-heptane and vacuum evaporated to remove the TBME. Removal of TBME resulted in precipitation of the desired S-monoester. Residual ethyl 3-[3',4'-dichlorophenyl]glutarate diester remains dissolved in n-heptane.
  • Multigram scale preparation of S-monoethyl ester using Chirazyme L-2 (liquid) Ethyl 3-[3',4'-dichlorophenyl]glutarate (20 g) was dispersed in 25 mM sodium phosphate buffer pH 7.5 (180 ml) using an impeller mixer mounted in a 3- neck round bottom jacketed glass flask (500 mL) equipped with an electrode and pH delivery tube connected to a pH stat. The mixture was stirred and adjusted to pH 7.5 at 30-38° C. The reaction was initiated with the addition of 10 ml of Chirazyme L-2 (liquid form) and pH 7.5 was maintained by automatic titration of 0.5 M sodium hydroxide.
  • Ethyl 3-[3',4'-dichlorophenyl]glutarate (50 kg) was dispersed in 10 mM sodium phosphate buffer pH - 8.0 ( 450 L) with agitation (impeller speed -100 rpm) at 40° C in a 300 gallon glass-lined reactor equipped with an in-vessel pH probe.
  • the reaction was initiated with the addition of 6.25 kg of Chirazyme L-2 (adsorbed on beads).
  • Control of reaction pH between 7.9 -8J was achieved manually by observing the in-vessel probe and manually adjusting a metering valve to regulate flow of caustic (0.5 M NaOH) from an adjacent feedbottle pressurized with 3 psi nitrogen.
  • a 93 % conversion yield was achieved at 38-40° C following 43 hours of incubation.
  • the reaction was terminated by removing the enzyme by filtration.
  • the enzyme filtercake was washed with 100 mM phosphate buffer pH -8.0 ( ⁇ 125L).
  • the filtercake wash and filtrate were combined in a 200 gallon reactor and the pH was adjusted to -4.2 using 10 % H 2 SO 4 followed by isolation of the precipitated product by filtration.
  • the acid precipitant was rinsed in situ with water (-100 L) and dried on trays in an air dryer, yielding 40.5 kg product in >99 % enantiomeric excess.
  • Dried cake from two batch reactions (-79 kg) was mixed with 6 kg of supercel and 320 L tert -butyl methyl ether (TBME).
  • Insoluble material and supercel were removed by filtration and rinsed with 110 L of TBME.
  • the rinse was combined with the filtrate and concentrated 2-3 fold by vacuum evaporation.
  • the TBME concentrate was mixed with - 640 L of n-heptane and vacuum evaporated to remove the TBME. Removal of TBME resulted in precipitation of the desired S-monoester. Residual ethyl 3-[3',4'- dichlorophenyl]glutarate remains dissolved in n-heptane.
  • Ethyl 3-[3',4'-dichlorophenyl]glutarate (6.5 kg) was dispersed in 25 mM sodium phosphate buffer pH - 8.0 ( -60 L) with agitation (impeller speed -100 rpm) at 30° C in a 50 gallon glass-lined reactor equiped with an in-vessel pH probe.
  • the reaction was initiated with the addition of 3.25 L of Chirazyme L-2 (liquid).
  • Control of reaction pH between 7.9 -8J was achieved manually by observing the in-vessel probe and manually adjusting a metering valve to regulate flow of caustic (0.5 M NaOH) from an adjacent portable can pressurized with nitrogen (20 psi).
  • the TBME concentrate was mixed with - 110 L of n-heptane and vacuum evaporated to remove the TBME. Removal of TBME resulted in precipitation of the desired S-monoester. Residual ethyl 3-[3',4'- dichlorophenyljglutarate remains dissolved in n-heptane. The precipitated slurry was filtered and the filtercake dried in a vacuum oven yielding a white powder; 9.7 kg, 81.4%) molar yield; > 99% enantiomeric excess.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A process is provided for preparing an S-enantiomer compound having formula (IA) in enantiomeric excess, or an R-enantiomer compound having formula (IB) in enantiomeric excess, said process comprising hydrolyzing a compound having formula (II) with: (a) an enzyme capable of producing an enantiomeric excess of the S-enantiomer compound of formula (IA) of at least 70 %, or (b) an enzyme capable of producing an enantiomeric excess of the R-enantiomer compound of formula (IB) of at least 70 %, wherein R1 is selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, or cycloalkylalkyl.

Description

ENANTIOSELECTIVE ENZYMATIC HYDROLYSIS OF 3-SUBSTITUTED
ESTERS OF GLUTARIC ACID
BACKGROUND OF THE INVENTION
Substituted oximes are useful pharmaceutical compounds. For example, International Application No. PCT/US98/23255, filed November 18, 1998, describes certain substituted oximes that are useful as neurokinin antagonists. In many instances, it is desireable to produce a particular enantiomer of the substituted oxime. Thus, any efficient enantioselective process for producing a chiral intermediate for these compounds would be a welcome contribution to the art. This invention provides such a contribution.
SUMMARY OF THE INVENTION
This invention provides a process for preparing an S-enantiomer compound having the formula
Figure imgf000003_0001
in enantiomeric excess, or an R-enantiomer compound having the formula
Figure imgf000003_0002
in enantiomeric excess, said process comprising hydrolyzing a compound having the formula
Figure imgf000004_0001
with:
(a) an enzyme capable of producing an enantiomeric excess of the S- enantiomer compound of formula (IA) of at least 70%, or
(b) an enzyme capable of producing an enantiomeric excess of the R- enantiomer compound of formula (IB) of at least 70%, wherein R1 is selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, or cycloalkylalkyl.
DETAILED DESCRIPTION OF THE INVENTION As used herein, the term "alkyl" means straight or branched hydrocarbon chains of 1 to 6 carbon atoms, optionally substituted with one or more halo, hydroxy, or alkoxy substituents.
"Alkoxy" refers to a group having the formula R-O-, wherein R is alkyl. "Aryl" refers to a carbocyclic group having at least one aromatic ring (e.g., phenyl or naphthyl), optionally substituted with one or more substituents selected from halo, alkyl, hydroxy, alkoxy, or -CF3.
"Aralkyl" refers to a group having the formula aryl-R-, wherein R is alkyl. "Cycloalkyl" refers to a non-aromatic carbocyclic ring of from 3 to 6 carbon atoms, optionally substituted with one or more substituents selected from halo, alkyl, hydroxy, alkoxy, or -CF3.
"Cycloalkylalkyl" refers to a group having the formula cycloalkyl-R-, wherein R is alkyl.
"Halo" refers to fluorine, chlorine, bromine or iodine. "Et" refers to an ethyl group. "Enantiomeric excess" is calculated according to the following formula:
[ R ] - [ S] I e.e. % x 100%
[ R ] + [ S ] where [R] is the concentration of the R-enantiomer, and [S] is the concentration of the S-enantiomer.
R1 is preferably alkyl, more preferably methyl or ethyl, most preferably ethyl. Enzymes suitable for use in the present process can be identified by carrying out the screening procedure described in Example 1, below. The enzyme is preferably one that is capable of producing an e.e. of the desired compound of at least 80%, more preferably at least 90%. Preferably, the enzyme is one that produces the S-enantiomer compound in enantiomeric excess. Preferably, the enzymes used for preparing the S-enantiomer compound of formula (IA) are produced by Candida rugosa , Candida cylindracea , Candida antarctica , and Rhizopus delemar . Examples of enzymes suitable for use in preparing the S-enantiomer compound of formula (IA) include, but are not limited to, the following commercially available enzyme preparations: Altus ChiroCLEC CRO (Candida rugosa); Altus ChiroCLEC-CR (Candida rugosa); Altus Lipase CR Analytical Grade 001-C (Candida rugosa); Biocatalysts Ltd. (Candida cylindracea); Meito Sangyo LIPASE-OF (Candida cylindracea); Boehringer Mannheim Cholesterol Esterase (Candida rugosa); Boehringer Mannheim CHIRAZYME L-2 (Candida antarctica, fraction B); Fluka Lipase (Candida antarctica); Genzyme Lipase (Candida cyclindracea); Novo Nordisk Novozym 435 (Candida antarctica, type B); Novo Nordisk SP 525 (Candida antarctica, type B); and Seikagaki Lipase (Rhizopus delemar). Of these commercially available enzyme preparations, Boehringer Mannheim CHIRAZYME L-2, in either the dry or liquid form, and Novo Nordisk Novozym 435 (Candida antarctica, type B), in either the dry or liquid form, are particularly preferred.
Preferably, the enzymes used for preparing the R-enantiomer compound of formula (IB) are obtained from porcine or bovine pancreas. Examples of enzymes suitable for use in preparing the R-enantiomer compound of formula (IB) include, but are not limited to, the following commercially available enzyme preparations: Biocatalysts Ltd. Lipase (porcine pancreas); Boehringer Mannheim Lipase (porcine pancreas); Boehringer Mannheim CHIRAZYME L-7 Lipase (porcine pancreas); Rohm Tech COROLASE PP (porcine pancreas); Scientific Protein Labs. PEC High Lipase; Sigma α - Chymotrypsin Type II (bovine pancreas); Sigma Trypsin (porcine pancreas); Sigma Lipase Type II (porcine pancreas); ThermoGen ThermoCat E001; ThermoGen ThermoCat E002; ThermoGen ThermoCat E003; ThermoGen ThermoCat E004; ThermoGen ThermoCat E005; ThermoGen ThermoCat E006; ThermoGen ThermoCat E007; ThermoGen ThermoCat E008; ThermoGen ThermoCat E009; ThermoGen ThermoCat E010; ThermoGen ThermoCat E011; ThermoGen ThermoCat E012; ThermoGen ThermoCat E013; ThermoGen ThermoCat E014; ThermoGen ThermoCat E015; ThermoGen ThermoCat E016; ThermoGen ThermoCat E017B; ThermoGen ThermoCat 018; ThermoGen ThermoCat 019; ThermoGen ThermoCat 020; and ThermoGen
ThermoCat 027. Of these commercially available enzyme preparations, Sigma α - Chymotrypsin Type II and Boehringer Mannheim CHIRAZYME L-7 are particularly preferred.
The hydrolysis of compound (II) is preferably carried out at a pH of 5-9, more preferably 6 - 8.5, most preferably 7-8. Preferably, the substrate concentration is 5% to 25%, more preferably 8% to 12%. Preferably, the hydrolysis is carried out at a temperature of 25° to 45° C, more preferably, 30° to 40° C. The hydrolysis is preferably carried out in the presence of a buffer (e.g., sodium phosphate or potassium phosphate buffer), and the reaction may, if desired, be titrated with a caustic titrant (e.g., NaOH solution) to maintain the pH within the preferred range. Preferably, the concentration of the caustic titrant is 0.2 to 1 M, preferably about 0.5 M. In a particularly preferred embodiment, compound (II) is dispersed in a buffer solution by agitation, and the enzyme is subsequently added to the mixture. Upon adding the enzyme, the reaction mixture is agitated until the desired degree of hydrolysis is reached. When using an enzyme in solid form (e.g., adsorbed on beads), the reaction may be terminated by removing the enzyme by filtration, and adding acid (e.g., H2SO4) to the filtrate to adjust the pH to about 4.0- 4.5, thereby precipitating the desired product. When using a liquid enzyme, the reaction may be terminated by adding acid (e.g., H2SO4) to adjust the pH to about 4.0-4.5, and the precipitated product can be recovered by filtration.
Compound (II) may be made by conventional means, e.g., as shown in the scheme below: CH3COCH2COOEt
piperidine, EtOH
Figure imgf000007_0002
Figure imgf000007_0001
Figure imgf000007_0003
Figure imgf000007_0004
As shown in the scheme above, aldehyde (1) is condensed with ethyl acetoacetate in ethyl alcohol with a piperidine catalyst to form crude reaction product (2), a mixture of 2 isomers. The condensation is preferably carried out over 2-3 days at 20°C ± 5°C. Potassium hydroxide is added to the crude reaction product (2), and heated at about 60°-70°C for about one hour to form dipotassium salt (3), which is filtered and washed with ethyl alcohol. The dipotassium salt is dissolved in water and treated with HC1 to form compound (4). Compound (4) is reacted with an alcohol, R^H (e.g., ethyl alcohol) in the presence of p-toluenesulfonic acid to form compound (II). Compound (II) may be isolated and purified by adding a higher boiling solvent, (e.g., heptane), distilling off the alcohol, washing with dilute sodium bicarbonate solution to remove the p-toluenesulfonic acid, and cooling the solution to precipitate compound (II).
The following examples illustrate the foregoing invention, although such examples should not be construed as limiting the scope of the invention. Alternative reagents and analagous processes within the scope of the invention will be apparent to those skilled in the art.
EXAMPLES
EXAMPLE 1
Enzyme screening reactions were conducted using 1-30 mg enzyme suspended in 0.9 ml of 50 mM sodium phosphate buffer pH 7. The reaction was initiated upon addition of ethyl 3-[3',4'-dichlorophenyl]glutarate (-25 mg) dissolved in 0J ml acetone (10% v/v). Following 48 hours of incubation in 1 dram vials at 30° C with agitation (225 rpm), the reactions were terminated by acidification to a pH of less than 2 using 6N HC1 and extracted with 2 ml ethyl acetate prior to analysis by reverse-phase and chiral HPLC. Enzymes generating the R -monoester or the S -monoester in > 87% enantiomeric excess are summarized in Tables 1 and 2, respectively.
Table 1. Enzymes identified to selectively hydrolyze precursor ethyl 3-[3',4'- dichlorophenyl]glutarate yielding R - monoacid.
Figure imgf000008_0001
Figure imgf000009_0002
Table 2. Enzymes identified to selectively hydrolyze precursor ethyl 3-[3',4'- dichlorophenyl]glutarate yielding S - monoacid.
Figure imgf000009_0001
Figure imgf000009_0003
Figure imgf000010_0001
EXAMPLE 2
Multigram scale preparation of R-monoethyl ester:
Ethyl 3-(3',4'-dichlorophenyl)glutarate (2.45 g, 7.35 mmol) was added to 50 mM KC1 (400 mL) in a 3-neck round bottom flask equipped with an electrode and pH delivery tube connected to a pH stat. The mixture was stirred and adjusted to pH 7-8. α-chymotrypsin (Sigma Type II; bovine pancreas) (1.25 g) was added and the pH was maintained at pH 8 by automatic titration of 0.5 M NaOH. The reaction was terminated after 114 hours. The reaction mixture was evaporated to dryness and the resultant solid triturated with methyl ene chloride (200 mL). The slurry was filtered and the filtrate evaporated to dryness to obtain a pink oil which slowly solidified: 2J2 g, 94.6% yield; >95% enantiomeric excess; []25 D = -5.77 (c = 1.11, EtOH).
EXAMPLE 3
Multigram scale preparation of S-monoethyl ester using Chirazyme L-2 (adsorbed on beads):
Ethyl 3-[3',4'-dichlorophenyl]glutarate (135 g) was dispersed in 10 mM sodium phosphate buffer pH 8.0 (1215 ml) using an impeller mixer mounted in a 3-neck round bottom jacketed glass flask (3L) equipped with an electrode and pH delivery tube connected to a pH stat. The mixture was stirred and adjusted to pH 8 at 40° C. The reaction was initiated with the addition of 33.75 g of Chirazyme L-2 (adsorbed on beads) and pH 8.0 was maintained by automatic titration of 0.5 M sodium hydroxide. Following 24 hours of incubation, the reaction was 96%> monoester as measured by HPLC. The reaction was terminated by removing the enzyme by filtration. The pH of the filtrate was adjusted to 4.0-4.5 using 20% H2SO4 followed by isolation of the precipitated product by filtration. The acid precipitant was dried (vacuum dryer), and then dissolved in 300 ml of tert -butyl methyl ether (TBME). Insoluble material was removed by filtration through celite. The TBME filtrate was mixed with 400-600 ml of n-heptane and vacuum evaporated to remove the TBME. Removal of TBME resulted in precipitation of the desired S-monoester. Residual ethyl 3-[3',4'-dichlorophenyl]glutarate diester remains dissolved in n-heptane. The precipitated slurry was filtered and the filtercake dried in a vacuum oven yielding a fluffy white powder; 104.07 g, 84% molar yield; > 99%> enantiomeric excess. Molar yields of 98%) S- monoester in >99 % enantiomeric excess were obtained using similar conversion conditions employing 5 g of Chirazyme L-2 (covalently bound to beads) and 20 g of ethyl 3- [3',4'-dichlorophenyl]glutarate.
EXAMPLE 4
Multigram scale preparation of S-monoethyl ester using Chirazyme L-2 (liquid): Ethyl 3-[3',4'-dichlorophenyl]glutarate (20 g) was dispersed in 25 mM sodium phosphate buffer pH 7.5 (180 ml) using an impeller mixer mounted in a 3- neck round bottom jacketed glass flask (500 mL) equipped with an electrode and pH delivery tube connected to a pH stat. The mixture was stirred and adjusted to pH 7.5 at 30-38° C. The reaction was initiated with the addition of 10 ml of Chirazyme L-2 (liquid form) and pH 7.5 was maintained by automatic titration of 0.5 M sodium hydroxide. Molar yields of >95% S -monoester in >99% enantiomeric excess were achieved following 24-32 hours of incubation based on volume of titrant added and chiral HPLC analysis. The reaction was terminated by adjusting the pH to 4.0-4.5, followed by isolation of the precipitated product as outlined in Example 3.
EXAMPLE 5
Pilot scale kg preparation of S-monoethyl ester using Chirazyme L-2 (adsorbed on beads):
Ethyl 3-[3',4'-dichlorophenyl]glutarate (50 kg) was dispersed in 10 mM sodium phosphate buffer pH - 8.0 ( 450 L) with agitation (impeller speed -100 rpm) at 40° C in a 300 gallon glass-lined reactor equipped with an in-vessel pH probe. The reaction was initiated with the addition of 6.25 kg of Chirazyme L-2 (adsorbed on beads). Control of reaction pH between 7.9 -8J was achieved manually by observing the in-vessel probe and manually adjusting a metering valve to regulate flow of caustic (0.5 M NaOH) from an adjacent feedbottle pressurized with 3 psi nitrogen. A 93 % conversion yield was achieved at 38-40° C following 43 hours of incubation. The reaction was terminated by removing the enzyme by filtration. The enzyme filtercake was washed with 100 mM phosphate buffer pH -8.0 (~ 125L). The filtercake wash and filtrate were combined in a 200 gallon reactor and the pH was adjusted to -4.2 using 10 % H2SO4 followed by isolation of the precipitated product by filtration. The acid precipitant was rinsed in situ with water (-100 L) and dried on trays in an air dryer, yielding 40.5 kg product in >99 % enantiomeric excess. Dried cake from two batch reactions (-79 kg) was mixed with 6 kg of supercel and 320 L tert -butyl methyl ether (TBME). Insoluble material and supercel were removed by filtration and rinsed with 110 L of TBME. The rinse was combined with the filtrate and concentrated 2-3 fold by vacuum evaporation. The TBME concentrate was mixed with - 640 L of n-heptane and vacuum evaporated to remove the TBME. Removal of TBME resulted in precipitation of the desired S-monoester. Residual ethyl 3-[3',4'- dichlorophenyl]glutarate remains dissolved in n-heptane. The precipitated slurry was filtered and the filtercake was dried in a vacuum oven, yielding a white powder; 75.2 kg, 82.1% molar yield; > 99% enantiomeric excess; []20 D = + 6.9 (c =1.0075, EtOH). EXAMPLE 6
Pilot scale kg preparation of S-monoethyl ester using Chirazyme L-2 (liquid):
Ethyl 3-[3',4'-dichlorophenyl]glutarate (6.5 kg) was dispersed in 25 mM sodium phosphate buffer pH - 8.0 ( -60 L) with agitation (impeller speed -100 rpm) at 30° C in a 50 gallon glass-lined reactor equiped with an in-vessel pH probe. The reaction was initiated with the addition of 3.25 L of Chirazyme L-2 (liquid). Control of reaction pH between 7.9 -8J was achieved manually by observing the in-vessel probe and manually adjusting a metering valve to regulate flow of caustic (0.5 M NaOH) from an adjacent portable can pressurized with nitrogen (20 psi). A 97%) molar yield was achieved at 30° C following 45 hours of incubation. The reaction was terminated by reducing the pH to -4.2 using 10% H2SO4 followed by isolation of the precipitated product by filtration. The acid precipitant was rinsed in situ with water (-13 L) and dried on trays in an air dryer, yielding 5.8 kg product in >99 % enantiomeric excess. Dried cake from two batch reactions (-11.4 kg) was mixed with 2 kg of supercel and 50 L tβrt -butyl methyl ether (TBME). Insoluble material and supercel were removed by filtration and rinsed with 11 L of TBME. The rinse was combined with the filtrate and concentrated 2-3 fold by vacuum evaporation. The TBME concentrate was mixed with - 110 L of n-heptane and vacuum evaporated to remove the TBME. Removal of TBME resulted in precipitation of the desired S-monoester. Residual ethyl 3-[3',4'- dichlorophenyljglutarate remains dissolved in n-heptane. The precipitated slurry was filtered and the filtercake dried in a vacuum oven yielding a white powder; 9.7 kg, 81.4%) molar yield; > 99% enantiomeric excess.
While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

Claims

WE CLAIM:
1. A process for preparing an S-enantiomer compound having the formula
Figure imgf000014_0001
in enantiomeric excess, or an R-enantiomer compound having the formula
Figure imgf000014_0002
in enantiomeric excess, said process comprising hydrolyzing a compound having the formula
Figure imgf000014_0003
with: (a) an enzyme capable of producing an enantiomeric excess of the S- enantiomer compound of formula (IA) of at least 70%>, or
(b) an enzyme capable of producing an enantiomeric excess of the R- enantiomer compound of formula (IB) of at least 70%>, wherein R1 is selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, or cycloalkylalkyl.
2. The method of claim 1 , wherein the enzyme used is one that produces an enantiomeric excess of the S-enantiomer of at least 70%.
3. The method of claim 2, wherein an enantiomeric excess of the S- enantiomer of at least 80% is produced.
4. The method of claim 3, wherein the hydrolysis is carried out at a temperature of from 25° to 45° C.
5. The method of claim 4, wherein an enantiomeric excess of the S- enantiomer of at least 90% is produced.
6. The method of claim 5, wherein the hydrolysis is carried out at a temperature of from 30° to 40° C.
7. The method of claim 6, wherein the hydrolysis is carried out in the presence of a buffer.
8. The method of claim 7, wherein the hydrolysis is carried out at a pH from 6-8.5.
9. The method of claim 8, wherein the enzyme is produced by an organism selected from the group consisting of Candida rugosa , Candida cylindracea , Candida antarctica , and Rhizopus delemar.
10. The method of claim 9, wherein the hydrolysis is carried out at a pH
11. The method of claim 1, wherein the enzyme used is one that produces an enantiomeric excess of the R-enantiomer of at least 70%.
12. The method of claim 11, wherein an enantiomeric excess of the R- enantiomer of at least 80%> is produced.
13. The method of claim 12, wherein the hydrolysis is carried out at a temperature of from 25° to 45° C.
14. The method of claim 13, wherein an enantiomeric excess of the R- enantiomer of at least 90% is produced.
15. The method of claim 14, wherein the hydrolysis is carried out at a temperature of from 30° to 40° C.
16. The method of claim 15, wherein the hydrolysis is carried out in the presence of a buffer.
17. The method of claim 16, wherein the hydrolysis is carried out at a pH
18. The method of claim 17, wherein the enzyme is obtained from porcine or bovine pancreas.
19. The method of claim 18, wherein the hydrolysis is carried out at a pH
PCT/US2000/004668 1999-02-26 2000-02-24 Enantioselective enzymatic hydrolysis of 3-substituted esters of glutaric acid Ceased WO2000050628A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU35005/00A AU3500500A (en) 1999-02-26 2000-02-24 Enantioselective enzymatic hydrolysis of 3-substituted esters of glutaric acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25947299A 1999-02-26 1999-02-26
US09/259,472 1999-02-26

Publications (1)

Publication Number Publication Date
WO2000050628A1 true WO2000050628A1 (en) 2000-08-31

Family

ID=22985103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/004668 Ceased WO2000050628A1 (en) 1999-02-26 2000-02-24 Enantioselective enzymatic hydrolysis of 3-substituted esters of glutaric acid

Country Status (3)

Country Link
AR (1) AR022725A1 (en)
AU (1) AU3500500A (en)
WO (1) WO2000050628A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010356A3 (en) * 2005-07-18 2007-08-23 Pfizer Ltd Process for the preparation of sulfonamide derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224019C1 (en) * 1982-06-28 1984-02-16 Takara Shuzo Co., Ltd., Kyoto Process for the preparation of alkyl beta -(S)-aminoglutarates
WO1993004058A1 (en) * 1991-08-22 1993-03-04 Chiroscience Limited Chiral glutarate esters, their resolution and derived glutarimide compounds
EP0812819A2 (en) * 1996-06-10 1997-12-17 Hüls Aktiengesellschaft Enantiomer-enriched tertiary hydrocarbonrest-substituted malonic acid ester and the preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224019C1 (en) * 1982-06-28 1984-02-16 Takara Shuzo Co., Ltd., Kyoto Process for the preparation of alkyl beta -(S)-aminoglutarates
WO1993004058A1 (en) * 1991-08-22 1993-03-04 Chiroscience Limited Chiral glutarate esters, their resolution and derived glutarimide compounds
EP0812819A2 (en) * 1996-06-10 1997-12-17 Hüls Aktiengesellschaft Enantiomer-enriched tertiary hydrocarbonrest-substituted malonic acid ester and the preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C.J. FRANCIS AND B. JONES: "Preparations of chiral delta-lactones via enantiotopically specific pig liver esterase-catalysed hydrolyses of 3-substituted glutaric acid diesters", J. CHEM SOC., CHEM COMMUN., no. 9, 1984, LONDON, UK, pages 579 - 580, XP002141862 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010356A3 (en) * 2005-07-18 2007-08-23 Pfizer Ltd Process for the preparation of sulfonamide derivatives
CN102051388B (en) * 2005-07-18 2013-03-27 辉瑞有限公司 Method of preparing compound

Also Published As

Publication number Publication date
AU3500500A (en) 2000-09-14
AR022725A1 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
US4857462A (en) Process for obtaining D(+)-naproxen
US6613934B1 (en) Enantiomerically enriched malonic acid monoesters substituted by a tertiary hydrocarbon radical, and their preparation
JP2707076B2 (en) Production method of optically active compound
EP0330529A1 (en) Process for the preparation of optically active 2-aryl-propionic acids
JPH022396A (en) Conversion of cephalosporine c and analogue to 7-aminocephalosporanic acid and its analogue by one stage enzymatic reaction
US4981789A (en) One-step enzymatic conversion of cephalosporin C and derivatives to 7-aminocephalosporanic acid and derivatives
FR2487375A1 (en) PROCESS FOR PRODUCING ENZYME CHOLESTERASE AND HYDROLYSIS OF CHOLESTEROL ESTERS OF FATTY ACIDS USING THE ENZYME ITSELF
WO2000050628A1 (en) Enantioselective enzymatic hydrolysis of 3-substituted esters of glutaric acid
EP0237983A2 (en) Process for the biotechnological preparation of L (-)-carnitine chloride
US6410306B1 (en) Enantioselective enzymatic hydrolysis of 3-substituted esters of glutaric acid
EP1313860B1 (en) Butinol i esterase
JPH08508639A (en) Enantioselective hydrolysis of Bouveraria basiana and its derived ketoprofen esters
CA2066926A1 (en) Process for the separation of the optical isomers of alphasubstituted carboxylic acids
US5010012A (en) Process for the enzymatic preparation of optically active phosphorus containing functional acetic acid derivatives
AU670088B2 (en) Enzymatic process to separate racemic mixtures of delta valerolactones
JP4042454B2 (en) Process for producing optically active 3-methylglutaric acid monoester
WO1998020152A1 (en) Process for producing optically active 3-quinuclidinol derivatives
US5248601A (en) Process for preparing L(-)-carnitine chloride
EP0344044B1 (en) Process for the preparation of optically active 2-aryloxy- or 2-arylthioalcanoic acids
JP3715662B2 (en) Process for producing optically active β-hydroxycarboxylic acid and its enantiomer ester
JP2005117905A (en) Process for producing optically active 1-benzyl-3-pyrrolidinol
JP3866357B2 (en) Thermostable, solvent-resistant esterase
JP2639651B2 (en) Process for producing optically active carboxylic acid and its enantiomer ester
JP3010382B2 (en) Method for producing (R) -2-propoxybenzene derivative
JPH0573396B2 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase